retatrutide phase 2 results obesity nejm 2023 🚨 BREAKING: Shows “Bariatric-Level” Weight Loss in 3 Trial New Phase 3 TRIUMPH-1 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most Medscape | The investigational triple

The capacity of these drugs to increase insulin secretion and suppress glucagon release leads not only to better blood sugar control but also to a better cardiovascular profile, putting them in a favorable position in the treatment of type 2 diabetes

Small, steady changes build lasting results far more effectively than extreme restrictions

Retatrutide increases resting metabolic rate, according to clinical studies

Many patients find that liquid nutrition is easier to tolerate than solid food, especially during the initial weeks of treatment

This combination of effects may explain why retatrutide has produced some of the strongest weight loss results observed in obesity research

Bettini S et al